Abstract

Background:The most dominant histopathologic type of ovarian cancer is epithelial ovarian cancer (EOC). Primary debulking surgery determines the treatment success and prognosis of advanced stage EOC. To maintain survival and progression, cancer cells need fatty acid synthase enzyme (FASN). The aim of this study was to evaluate preoperative serum FASN and CA 125 as predictors of primary debulking surgery results in patients with EOC. Methods:An observational cross-sectional study was performed on consecutive patients who underwent debulking surgery for suspected ovarian cancer at Dr. Hasan Sadikin Hospital Bandung from 2017 to 2019. Before debulking surgery, blood samples were examined for the serum levels of FASN and CA 125 using ELISA.Results:There were 53 patients enrolled in this study. Compared with the optimal debulking surgery group, the significant suboptimal debulking surgery group had significantly lower mean serum levels of FASN (0.46 ± 0.144 vs. 0.36 ± 0.128, p = 0.012) and CA 125 (964.22 ± 1722.5 vs. 264.98 ± 251.8, p = 0.002). The cutoff value was highest for the combination of FASN and CA 125 [410.06, area under the curve (AUC) = 77.5% (95% CI 65.5% to 81.9%, p = 0.001)] than for FASN alone [0.375, AUC = 71.3% (95% CI 56.8% to 85.8%, p = 0.009)] and CA 125 alone [222.5, AUC = 75.3% (95% CI 62.5% to 88.1%, p =0.002)]. Conclusion:The serum levelof FASN was correlated with suboptimal debulking surgery.

Highlights

  • Ovarian cancer is the most fatal malignancy in women, with a reported incidence of 239,000 each year (Coalition, 2018)

  • An observational cross-sectional study was performed on consecutive patients who underwent debulking surgery for suspected ovarian cancer at Dr Hasan Sadikin Hospital Bandung from 2017 to 2019

  • Blood samples were examined for the serum levels of fatty acid synthase enzyme (FASN) and CA 125 using ELISA

Read more

Summary

Introduction

Ovarian cancer is the most fatal malignancy in women, with a reported incidence of 239,000 each year (Coalition, 2018). In advanced stage EOC, the size of residual tumor after primary debulking surgery determines the success and prognosis of adjuvant chemotherapy (Chesnais et al, 2017). The survival rate of ovarian cancer was reported to be prolonged by 18–39 months in patients who have received optimal debulking surgery (Shashikant and Kesterson Joshua, 2009). Primary debulking surgery determines the treatment success and prognosis of advanced stage EOC. The aim of this study was to evaluate preoperative serum FASN and CA 125 as predictors of primary debulking surgery results in patients with EOC. Compared with the optimal debulking surgery group, the significant suboptimal debulking surgery group had significantly lower mean serum levels of FASN (0.46 ± 0.144 vs 0.36 ± 0.128, p = 0.012) and CA 125 (964.22 ± 1722.5 vs 264.98 ± 251.8, p = 0.002). Conclusion: The serum levelof FASN was correlated with suboptimal debulking surgery

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call